Zydus Lifesciences announced that it has received final approval from the United States Food and Drug Administration to market Telmisartan tablets, a generic version of a commonly prescribed blood pressure medication. Telmisartan is used to manage hypertension and is also indicated to reduce the risk of cardiovascular events such as heart attack and stroke in eligible patients. With this approval, Zydus can manufacture and market the drug in multiple strengths for the USA, further strengthening its presence in the cardiovascular therapeutics segment.

The approval marks another milestone in Zydus’ efforts to expand its generics portfolio in the United States, which remains one of the company’s key growth markets. Telmisartan tablets will be produced at Zydus’ manufacturing facility in India, aligning with the company’s strategy to leverage its domestic capabilities for global supply. Hypertension continues to be one of the most prevalent chronic conditions worldwide, driving demand for affordable treatment options, and the introduction of a generic version is expected to support wider patient access.

Zydus Lifesciences has been steadily increasing its product pipeline in the US, securing approvals across various therapeutic areas. The company said the latest approval reinforces its commitment to providing high-quality, cost-effective medicines to global healthcare systems and patients.